(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Neal Shore discussing patient-reported outcomes in a randomized phase 1 study of mevrometostat ...

SAN FRANCISCO -- The investigational Selution drug-coated balloon (DCB or DEB) edged closer to primetime in percutaneous coronary intervention (PCI), following the release of two noninferiority trials ...

VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in the first-ever randomized controlled trial (RCT) of the drug in people with ...

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...

Schizophrenia patients on antipsychotics lost significantly more weight and had a greater reduction in HbA1c with 1 mg semaglutide than placebo. Patients with severe psychiatric disorders and those ...

A diabetes drug may hold the key to slowing the aging process. New research finds semaglutide decelerates biological aging in people with HIV, sparking hope for broader longevity breakthroughs. Study: ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic benefits during treatment. A large-scale, randomized, phase 3 trial, part of ...

Background: Although medications exist to effectively treat opioid use disorder (OUD), treatment retention is a pressing challenge. Peer recovery specialists (PRSs) may play an important role in OUD ...

CHICAGO — Once-weekly semaglutide improved glycemia and reduced weight without increasing hypoglycemia in adults with type 1 diabetes (T1D) and obesity, new research presented at the American Diabetes ...

A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ingestive behavior in adults with ...

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ...